Continuing along this pathway, MAPK inhibition using EGFR and MEK inhibitors prevented expression of PD-L1 at the transcriptional and translational levels in non-small cell lung cancer (NSCLC) [73]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.